Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling
Abstract Background Quantitative susceptibility mapping (QSM) and dynamic contrast enhanced quantitative perfusion (DCEQP) MRI sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cavernous angiomas. We assessed their prospective changes in cavernous angiomas with symptomatic hemorrhage (CASH) in a multisite trial readiness project (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</jats:ext-link><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT03652181">NCT03652181</jats:ext-link>).Methods Patients with CASH in the prior year, without prior or planned lesion resection or irradiation were enrolled. Mean QSM and DCEQP of CASH lesion were acquired at baseline, and at 1- and 2-year follow-ups. Sensitivity and specificity of biomarker changes were analyzed in relation to predefined lesional symptomatic hemorrhage (SH) or asymptomatic change (AC). Sample size calculations for hypothesized therapeutic effects were conducted.Results We logged 143 QSM and 130 DCEQP paired annual assessments. Annual QSM change was greater in cases with SH than in cases without SH (p= 0.019). Annual QSM increase by ≥ 6% occurred in 7 of 7 cases (100%) with recurrent SH and in 7 of 10 cases (70%) with AC during the same epoch, and 3.82 times more frequently than clinical events. DCEQP change had lower sensitivity for SH and AC than QSM change, and greater variance. A trial with smallest sample size would detect a 30% difference in QSM annual change in 34 or 42 subjects (one and two-tailed, respectively), power 0.8, alpha 0.05.Conclusions Assessment of QSM change is feasible and sensitive to recurrent bleeding in CASH. Evaluation of an intervention on QSM percent change may be used as a time-averaged difference between 2 arms using a repeated measures analysis. DCEQP change is associated with lesser sensitivity and higher variability than QSM. These results are the basis of an application for certification by the U.S. F.D.A. of QSM as a biomarker of drug effect in CASH..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 08. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hage, Stephanie [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.06.01.23290854 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI039799840 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI039799840 | ||
| 003 | DE-627 | ||
| 005 | 20231205144947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230606s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.06.01.23290854 |2 doi | |
| 035 | |a (DE-627)XBI039799840 | ||
| 035 | |a (biorXiv)10.1101/2023.06.01.23290854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hage, Stephanie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Quantitative susceptibility mapping (QSM) and dynamic contrast enhanced quantitative perfusion (DCEQP) MRI sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cavernous angiomas. We assessed their prospective changes in cavernous angiomas with symptomatic hemorrhage (CASH) in a multisite trial readiness project (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</jats:ext-link><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT03652181">NCT03652181</jats:ext-link>).Methods Patients with CASH in the prior year, without prior or planned lesion resection or irradiation were enrolled. Mean QSM and DCEQP of CASH lesion were acquired at baseline, and at 1- and 2-year follow-ups. Sensitivity and specificity of biomarker changes were analyzed in relation to predefined lesional symptomatic hemorrhage (SH) or asymptomatic change (AC). Sample size calculations for hypothesized therapeutic effects were conducted.Results We logged 143 QSM and 130 DCEQP paired annual assessments. Annual QSM change was greater in cases with SH than in cases without SH (p= 0.019). Annual QSM increase by ≥ 6% occurred in 7 of 7 cases (100%) with recurrent SH and in 7 of 10 cases (70%) with AC during the same epoch, and 3.82 times more frequently than clinical events. DCEQP change had lower sensitivity for SH and AC than QSM change, and greater variance. A trial with smallest sample size would detect a 30% difference in QSM annual change in 34 or 42 subjects (one and two-tailed, respectively), power 0.8, alpha 0.05.Conclusions Assessment of QSM change is feasible and sensitive to recurrent bleeding in CASH. Evaluation of an intervention on QSM percent change may be used as a time-averaged difference between 2 arms using a repeated measures analysis. DCEQP change is associated with lesser sensitivity and higher variability than QSM. These results are the basis of an application for certification by the U.S. F.D.A. of QSM as a biomarker of drug effect in CASH. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Kinkade, Serena |4 aut | |
| 700 | 1 | |a Girard, Romuald |4 aut | |
| 700 | 1 | |a Flemming, Kelly D. |0 (orcid)0000-0001-6021-1190 |4 aut | |
| 700 | 1 | |a Kim, Helen |0 (orcid)0000-0002-1937-354X |4 aut | |
| 700 | 1 | |a Torbey, Michel T. |0 (orcid)0000-0001-8187-9683 |4 aut | |
| 700 | 1 | |a Huang, Judy |4 aut | |
| 700 | 1 | |a Huston, John |0 (orcid)0000-0003-0584-9460 |4 aut | |
| 700 | 1 | |a Shu, Yunhong |4 aut | |
| 700 | 1 | |a Selwyn, Reed G. |4 aut | |
| 700 | 1 | |a Hart, Blaine L. |0 (orcid)0000-0001-5207-1087 |4 aut | |
| 700 | 1 | |a Mabray, Marc C. |0 (orcid)0000-0001-7355-6833 |4 aut | |
| 700 | 1 | |a Feghali, James |0 (orcid)0000-0001-7168-4751 |4 aut | |
| 700 | 1 | |a Sair, Haris I. |4 aut | |
| 700 | 1 | |a Narvid, Jared |4 aut | |
| 700 | 1 | |a Lupo, Janine M. |4 aut | |
| 700 | 1 | |a Lee, Justine |4 aut | |
| 700 | 1 | |a Stadnik, Agnieszka |4 aut | |
| 700 | 1 | |a Alcazar, Roberto |0 (orcid)0000-0003-1214-5576 |4 aut | |
| 700 | 1 | |a Shenkar, Robert |0 (orcid)0000-0002-1300-6845 |4 aut | |
| 700 | 1 | |a Hobson, Nicholas |4 aut | |
| 700 | 1 | |a DeBiasse, Dorothy |4 aut | |
| 700 | 1 | |a Lane, Karen |4 aut | |
| 700 | 1 | |a McBee, Nichole |4 aut | |
| 700 | 1 | |a Treine, Kevin |4 aut | |
| 700 | 1 | |a Ostapkovich, Noeleen |4 aut | |
| 700 | 1 | |a Wang, Ying |4 aut | |
| 700 | 1 | |a Thompson, Richard E. |4 aut | |
| 700 | 1 | |a Mendoza-Puccini, Carolina |0 (orcid)0000-0002-3241-9303 |4 aut | |
| 700 | 1 | |a Koenig, James |0 (orcid)0000-0003-1930-6870 |4 aut | |
| 700 | 1 | |a Carroll, Timothy |0 (orcid)0000-0003-2113-6284 |4 aut | |
| 700 | 1 | |a Hanley, Daniel F. |0 (orcid)0000-0002-9536-4258 |4 aut | |
| 700 | 1 | |a Awad, Issam A. |0 (orcid)0000-0003-1510-602X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 08. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:08 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.06.01.23290854 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 08 |c 06 | ||